Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.5011784466177227 | N/A |
Market Cap | $82.65M | N/A |
Shares Outstanding | 164.92M | 12.57% |
Employees | 0 | N/A |
Shareholder Equity | 42.91M | -21.69% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 5.71 | N/A |
P/B Ratio | 1.93 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.2218 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $14.47M | N/A |
Earnings | -$9.52M | N/A |
Gross Margin | 0.6257 | N/A |
Operating Margin | -0.6904 | N/A |
Net income margin | -0.6579 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $33.24M | N/A |
Cash on Hand | $11.07M | N/A |
Debt to Equity | 0.0973 | 62.23% |
Current Ratio | $5.99 | -43.80% |